Skip to main content
Smart Investors Daily
CD

NASDAQ · CDIO

Cardio Diagnostics Holdings, Inc.

Healthcare · Biotechnology

$2.02

Down-$0.01 (-0.49%)

Updated Sep 19, 2026, 2:35 PM

SID Score

4.5/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
7.1M
P/E ratio
-1.08
Dividend yield
0.00%
52-week range
$0.97 – $7.91
Volume
71.62K
Avg. volume
35.8K

Price performance

CDIO price history

1M range · 20 trading sessions · Daily adjusted prices

CDIO closed at $2.02 after 20 trading sessions, down 0.49% for the selected period.

Last close
$2.02
Period change
-0.49%
Period low
$1.83
Period high
$2.07
Daily close
View OHLC price history
CDIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$2.04$2.1634$1.92$2.0271.62K
Sep 17, 2026$2.00$2.0656$2.00$2.0327.75K
Sep 16, 2026$1.9901$2.06$1.92$2.0032.96K
Sep 15, 2026$2.15$2.16$1.92$2.0063.32K
Sep 14, 2026$2.03$2.14$2.025$2.0721.67K
Sep 11, 2026$2.05$2.09$1.98$2.0325.22K
Sep 10, 2026$2.02$2.14$1.98$1.9824.31K
Sep 9, 2026$1.98$2.09$1.95$2.0754.73K
Sep 8, 2026$1.88$2.10$1.85$1.9658.15K
Sep 4, 2026$1.8498$1.86$1.82$1.8610.25K
Sep 3, 2026$1.85$1.925$1.83$1.8389.89K
Sep 2, 2026$1.81$1.89$1.81$1.8417.8K
Sep 1, 2026$1.87$1.87$1.805$1.858.47K
Aug 31, 2026$1.83$1.88$1.80$1.8722.54K
Aug 28, 2026$1.90$1.90$1.81$1.8514.13K
Aug 27, 2026$1.92$1.92$1.85$1.8724.24K
Aug 26, 2026$1.93$1.9499$1.8062$1.9325.83K
Aug 25, 2026$1.89$2.00$1.86$1.9126.3K
Aug 24, 2026$2.03$2.1699$1.88$1.92551.71K
Aug 21, 2026$2.19$2.19$1.9601$2.0336.87K

Latest CDIO news

The latest Smart Investors Daily articles mentioning CDIO.

CDIO research

Overview

Company profile and research snapshot.

Company profile

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$61.20
Implied upside
Analysts
7
CDIO recent ratings
DateFirmRatingTarget
Aug 27, 2024BenchmarkSpeculative Buy
Jun 6, 2024BenchmarkSpeculative Buy
Apr 19, 2024BenchmarkSpeculative Buy
Jun 15, 2023BenchmarkSpeculative Buy
May 22, 2023Northland Capital MarketsOutperform
Open full forecast

News briefing

No generated briefing is available yet.

ChartMill · Mar 2, 2026

Monday's session: top gainers and losers

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.